FDA Grants Fast Track Designation for Reneo Pharma’s Mavodelpar (REN001) for LCHAD Deficiency Treatment
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing and commercialising therapies for patients with rare genetic mitochondrial diseases granted Fast Track design ...
FLAG Therapeutics’ FLAG-003 Receives Rare Pediatric Disease Designation from FDA for Diffuse Intrinsic Pontine Glioma (DIPG) Treatment
FLAG Therapeutics announces FLAG-003 granted Rare Pediatric Disease designation by FDA. FLAG-003 is an investigational therapy for treating Diffuse Intrinsic Pontine Glioma (DIPG), a rare, aggressive ...